FDA Approves First Menin Inhibitor for Acute Leukemia

(MedPage Today) -- The FDA granted full approval to the menin inhibitor revumenib (Revuforj) for adults and children 1 year and older with relapsed/refractory acute leukemia and a lysine methyltransferase 2A gene (KMT2A) translocation.
Support...